Research Topics
Species | Erik De ClercqSummaryAffiliation: Katholieke Universiteit Leuven Country: Belgium Publications
| Collaborators
|
Detail Information
Publications
Emerging antiviral drugsErik De Clercq
Katholieke Universiteit Leuven, Rega Institute for Medical Research, Minderbroedersstraat 10, B 3000 Leuven, Belgium
Expert Opin Emerg Drugs 13:393-416. 2008....
The acyclic nucleoside phosphonates from inception to clinical use: historical perspectiveErik De Clercq
Rega Institute for Medical Research, K U Leuven, Minderbroedersstraat 10, B 3000 Leuven, Belgium
Antiviral Res 75:1-13. 2007..between Antonín Holý [Institute of Organic Chemistry and Biochemistry (IOCB, Prague, Czech Republic)] and Erik De Clercq (Rega Institute for Medical Research, K.U. Leuven, Belgium) started exactly 30 years ago...
Pre-exposure chemoprophylaxis of HIV infection: quo vadis?Erik De Clercq
Rega Institute for Medical Research, K U Leuven, Minderbroedersstraat 10, B 3000 Leuven, Belgium
Biochem Pharmacol 83:567-73. 2012..Other PrEP studies are still ongoing. Available data point to the efficacy and safety of TDF with or without FTC in the prophylaxis of HIV infection (AIDS)...
Yet another ten stories on antiviral drug discovery (part D): paradigms, paradoxes, and paraductionsErik De Clercq
Rega Institute for Medical Research, K U Leuven, Minderbroedersstraat 10, B 3000 Leuven, Belgium
Med Res Rev 30:667-707. 2010....
Another ten stories in antiviral drug discovery (part C): "Old" and "new" antivirals, strategies, and perspectivesErik De Clercq
Rega Institute for Medical Research, K U Leuven, Minderbroedersstraat 10, B 3000 Leuven, Belgium
Med Res Rev 29:611-45. 2009....
Antiviral drug discovery: ten more compounds, and ten more stories (part B)Erik De Clercq
Rega Institute for Medical Research, K U Leuven, Minderbroedersstraat 10, B 3000 Leuven, Belgium
Med Res Rev 29:571-610. 2009....
The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil)Erik De Clercq
Rega Institute for Medical Research, Minderbroedersstraat 10, B 3000 Leuven, Belgium
Biochem Pharmacol 77:1655-64. 2009....
Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIVErik De Clercq
Rega Institute for Medical Research, Department of Microbiology and Immunology, Katholieke Universiteit Leuven, Leuven, Belgium
Int J Antimicrob Agents 33:307-20. 2009..These compounds should be used in drug combination regimens to achieve the highest possible benefit, tolerability and compliance and to diminish the risk of resistance development...
Recent highlights in the development of new antiviral drugsErik De Clercq
Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, B 3000 Leuven, Belgium
Curr Opin Microbiol 8:552-60. 2005..e. human papilloma viruses, adenoviruses, human herpesvirus type 6, poxviruses, severe acute respiratory syndrome coronavirus and hemorrhagic fever viruses)...
Acyclic nucleoside phosphonates: past, present and future. Bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: the phosphonate bridgeE De Clercq
Rega Institute for Medical Research, K U Leuven, Minderbroedersstraat 10, B 3000 Leuven, Belgium
Biochem Pharmacol 73:911-22. 2007..e. PMPO-DAPy, PMEO-DAPy, HPMPO-DAPy) and cyclic nucleoside phosphonates (i.e. PMDTA, PMDTT, GS9148) have been accredited with an antiviral potency and selectivity similar to those of cidofovir, adefovir and/or tenofovir...
Antiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapyErik De Clercq
Rega Institute for Medical Research, K U Leuven, Minderbroedersstraat 10, B 3000 Leuven, Belgium
Br J Pharmacol 147:1-11. 2006..This review will chart the origins and development of the most important of the antiviral prodrugs to date...
Avian influenza A (H5N1) infection: targets and strategies for chemotherapeutic interventionErik De Clercq
Rega Institute for Medical Research, Minderbroedersstraat 10, B 3000 Leuven, Belgium
Trends Pharmacol Sci 28:280-5. 2007..As has been shown for other viral infections, RNA interference could be a powerful means with which to suppress the replication of avian H5N1...
In search of effective anti-HHV-6 agentsErik De Clercq
Rega Institute for Medical Research, K U Leuven, Minderbroedersstraat 10, B 3000 Leuven, Belgium
J Clin Virol 37:S82-6. 2006....
John Montgomery's legacy: carbocyclic adenosine analogues as SAH hydrolase inhibitors with broad-spectrum antiviral activityErik De Clercq
Rega Institute for Medical Research, Department of Microbiology and Immunology, K U Letven, Minderbroedersstraat 10, B 3000 Leuven, Belgium
Nucleosides Nucleotides Nucleic Acids 24:1395-415. 2005....
Potential antivirals and antiviral strategies against SARS coronavirus infectionsErik De Clercq
Rega Institute for Medical Research, KU Leuven, Minderbroedersstraat 10B 3000 Leuven, Belgium
Expert Rev Anti Infect Ther 4:291-302. 2006....
Antiviral agents active against influenza A virusesErik De Clercq
Rega Institute for Medical Research, Katholieke Universiteit Leuven, B 3000 Leuven, Belgium
Nat Rev Drug Discov 5:1015-25. 2006..This article reviews agents that have been shown to have activity against influenza A viruses and discusses their therapeutic potential, and also describes emerging strategies for targeting these viruses...
The history of antiretrovirals: key discoveries over the past 25 yearsErik De Clercq
Department of Microbiology and Immunology, Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
Rev Med Virol 19:287-99. 2009..These compounds are used in various drug combination (some at fixed dose) regimens so as to achieve the highest possible benefit and tolerability, and to diminish the risk of virus-drug resistance development...
In search of a selective therapy of viral infectionsErik De Clercq
Rega Institute for Medical Research, Department of Microbiology and Immunology, KU Leuven, Minderbroedersstraat 10, B 3000 Leuven, Belgium
Antiviral Res 85:19-24. 2010..This article forms part of a special issue of Antiviral Research marking the 25th anniversary of antiretroviral drug discovery and development, vol. 85, issue 1, 2010...
A new drug combination therapy for treatment-naive patients with HIV-1 infection, consisting of raltegravir, emtricitabine and tenofovir disoproxil fumarateErik De Clercq
Rega Institute for Medical Research, Minderbroedersstraat 10, B 3000 Leuven, Belgium
Expert Opin Pharmacother 10:2935-7. 2009..e. integrase and reverse transcriptase. These multiple (triple or quadruple) drug combinations should be aimed at once daily dosing...
Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizersErik De Clercq
Rega Institute for Medical Research, K U Leuven, Minderbroedersstraat 10, B 3000 Leuven, Belgium
Pharmacol Ther 128:509-18. 2010..e. AMD11070, AMD3465, KRH-3955, T-140, and 4F-benzoyl-TN14003), primarily as potential anti-HIV agents. They are all strong CXCR4 antagonists. Their role in stem cell mobilization remains to be assessed...
A 40-year journey in search of selective antiviral chemotherapyErik De Clercq
Department of Microbiology and Immunology, Rega Institute for Medical Research, Medical School University of Leuven, Belgium
Annu Rev Pharmacol Toxicol 51:1-24. 2011..This work, initiated in collaboration with the late Paul A.J. Janssen, eventually led to the identification of rilpivirine as perhaps an "ideal" NNRTI...
The clinical potential of the acyclic (and cyclic) nucleoside phosphonates: the magic of the phosphonate bondErik De Clercq
Department of Microbiology and Immunology, K U Leuven, Rega Institute for Medical Research, Minderbroedersstraat, Leuven, Belgium
Biochem Pharmacol 82:99-109. 2011....
Strategies for the treatment of dengue virus infections: a narrative accountErik De Clercq
Rega Institute for Medical Research, K U Leuven, Minderbroedersstraat 10, B 3000 Leuven, Belgium
Future Med Chem 2:601-8. 2010..For other compounds found to be effective against the dengue virus, including geneticin (G418) and FGI-106, the mechanism of action still remains unresolved...
Antiretroviral drugsErik De Clercq
Rega Institute for Medical Research, K U Leuven, Minderbroedersstraat 10, B 3000 Leuven, Belgium
Curr Opin Pharmacol 10:507-15. 2010..Combination of several anti-HIV drugs [often referred to as highly active antiretroviral therapy (HAART)] has drastically altered AIDS from an almost uniformly fatal disease to a chronic manageable one...
The unabated synthesis of new nucleoside analogues with antiviral potential: a tribute to Morris J. RobinsErik De Clercq
Rega Institute for Medical Research, K U Leuven, Leuven, Belgium
Nucleosides Nucleotides Nucleic Acids 28:586-600. 2009..The furo[2,3-d]pyrimidin-2(3H)-one is the key structural determinant in the exquisitely potent activity of its derivatives (R = 2-deoxyribosyl; R' = p-pentylphenyl) against VZV (varicella-zoster virus) replication. [structure: see text]...
Historical perspectives in the development of antiviral agents against poxvirusesErik De Clercq
Rega Institute for Medical Research, Department of Microbiology and Immunology, Minderbroedersstraat 10, B 3000 Leuven, Belgium E Mail Tel 32 16 337367
Viruses 2:1322-39. 2010....
New developments in anti-HIV chemotherapyErik De Clercq
Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, Leuven, Belgium
Biochim Biophys Acta 1587:258-75. 2002....
Strategies in the design of antiviral drugsErik De Clercq
Rega Institute for Medical Research, Katholieke Universiteit Leuven, B 3000 Leuven, Belgium
Nat Rev Drug Discov 1:13-25. 2002..Here, I describe the rationale behind current and future drug-based strategies for combating viral infections...
Antiretroviral activity of semisynthetic derivatives of glycopeptide antibioticsJan Balzarini
Rega Institute for Medical Research, Katholieke Universiteit Leuven, B 3000 Leuven, Belgium
J Med Chem 46:2755-64. 2003..The mode of anti-HIV action of the antibiotic aglycon derivatives could be ascribed to inhibition of the viral entry process...
Substituted imidazopyridines as potent inhibitors of HCV replicationInge Vliegen
Rega Institute for Medical Research, KU Leuven, Minderbroedesstraat 10, 3000 Leuven, Belgium
J Hepatol 50:999-1009. 2009..The particular characteristics of one of the most potent compounds in this series (5-[[3-(4-chlorophenyl)-5-isoxazolyl]methyl]-2-(2,3-difluorophenyl)-5H-imidazo[4,5-c]pyridine or GS-327073), were studied...
The N137 and P140 amino acids in the p51 and the P95 amino acid in the p66 subunit of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase are instrumental to maintain catalytic activity and to design new classes of anti-HIV-1 drugsJoeri Auwerx
Rega Institute for Medical Research, K.U. Leuven, Belgium
FEBS Lett 579:2294-300. 2005....
DNA polymerase mutations in drug-resistant herpes simplex virus mutants determine in vivo neurovirulence and drug-enzyme interactionsGraciela Andrei
Laboratory of Virology, Rega Institute for Medical Research, K U Leuven, Belgium
Antivir Ther 12:719-32. 2007..It appears that drug-resistant mutants arising under the pressure of HPMP derivatives have the lowest levels of neurovirulence...
New anti-HIV agents and targetsErik De Clercq
Rega Institute for Medical Research, Katholieke Universiteit Leuven, B 3000 Leuven, Belgium
Med Res Rev 22:531-65. 2002..e., azapeptidic (atazanavir)) or non-peptidic scaffold (i.e., cyclic urea (mozenavir), 4-hydroxy-2-pyrone (tipranavir)). Non-peptidic PIs may be expected to inhibit HIV mutant strains that have become resistant to peptidomimetic PIs...
Antivirals and antiviral strategiesErik De Clercq
Rega Institute for Medical Research, Katholieke Universiteit Leuven, B 3000 Leuven, Belgium
Nat Rev Microbiol 2:704-20. 2004..Here, the virus infections for which antiviral therapy is needed and the compounds that are available, or are being developed, for the treatment of these infections are described...
Profile of resistance of human immunodeficiency virus to mannose-specific plant lectinsJan Balzarini
Rega Institute for Medical Research, Gent, Belgium
J Virol 78:10617-27. 2004..The plant lectins represent a well-defined class of anti-HIV (microbicidal) drugs with a novel HIV drug resistance profile different from those of other existing anti-HIV drugs...
The phenylmethylthiazolylthiourea nonnucleoside reverse transcriptase (RT) inhibitor MSK-076 selects for a resistance mutation in the active site of human immunodeficiency virus type 2 RTJoeri Auwerx
Rega Institute for Medical Research, B-3000 Leuven, Belgium
J Virol 78:7427-37. 2004..Our findings have important implications for the development of new NNRTIs with pronounced activity against a wider range of lentiviruses...
A novel, highly selective inhibitor of pestivirus replication that targets the viral RNA-dependent RNA polymeraseJan Paeshuyse
Rega Institute for Medical Research, Minderbroedersstraat 10, B-3000 Leuven, Belgium
J Virol 80:149-60. 2006..The potential of BPIP for the treatment of pestivirus and hepacivirus infections is discussed...
Inhibitory activities of three classes of acyclic nucleoside phosphonates against murine polyomavirus and primate simian virus 40 strainsIlya Lebeau
Rega Institute for Medical Research, K U Leuven, Minderbroedersstraat 10, Leuven, Belgium
Antimicrob Agents Chemother 51:2268-73. 2007..The last class showed the highest activities and selectivities against both polyomaviruses...
In vitro evaluation of the anti-orf virus activity of alkoxyalkyl esters of CDV, cCDV and (S)-HPMPAFabiana Dal Pozzo
Rega Institute for Medical Research, K U Leuven, Minderbroedersstraat 10, B 3000 Leuven, Belgium
Antiviral Res 75:52-7. 2007..Our results support the development of alkoxyalkyl esters of ANPs as antivirals not only for the treatment of complicated human orf lesions, but also in the therapy and prophylaxis of contagious ecthyma in sheep and goats...
Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture modelsSophie Duraffour
Rega Institute for Medical Research, K U Leuven, Minderbroedersstraat 10, Leuven, Belgium
Antimicrob Agents Chemother 51:4410-9. 2007..Our results demonstrate that compounds belonging to the newly synthesized ANPs, in addition to cidofovir, represent promising candidates for the treatment of poxvirus infections...
Antiviral potential of a new generation of acyclic nucleoside phosphonates, the 6-[2-(phosphonomethoxy)alkoxy]-2,4-diaminopyrimidinesErik De Clercq
Address correspondence to Erik De Clercq, Rega Institute for Medical Research, K U Leuven, Minderbroedersstraat 10, Leuven B 3000, Belgium
Nucleosides Nucleotides Nucleic Acids 24:331-41. 2005..The 6-[2-(phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines offer substantial potential for the treatment of a broad range of retro-, hepadna-, herpes-, adeno-, and poxvirus infections...
The discovery of antiviral agents: ten different compounds, ten different storiesErik De Clercq
Katholieke Universiteit Leuven, Rega Institute for Medical Research, Minderbroedersstraat 10, B 3000 Leuven, Belgium
Med Res Rev 28:929-53. 2008....
The thiazolobenzimidazole TBZE-029 inhibits enterovirus replication by targeting a short region immediately downstream from motif C in the nonstructural protein 2CArmando M De Palma
Rega Institute for Medical Research, Minderbroedersstraat 10, B 3000 Leuven, Belgium
J Virol 82:4720-30. 2008..The ATPase activity of 2C, however, remained unaltered in the presence of TBZE-029...
Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxisMyriam Witvrouw
Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
Antivir Ther 9:57-65. 2004..Co-receptor antagonists such as AMD3100 show promising anti-HIV-2 therapeutic modalities. Both AMD3100 and enfuvirtide could be used for prophylaxis against SHIV89.6...
Novel human immunodeficiency virus (HIV) inhibitors that have a dual mode of anti-HIV actionMiguel Stevens
Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium
Antimicrob Agents Chemother 47:3109-16. 2003....
N-aminoimidazole derivatives inhibiting retroviral replication via a yet unidentified mode of actionIrene M Lagoja
Laboratory of Medicinal Chemistry, Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, Belgium
J Med Chem 46:1546-53. 2003....
Susceptibility of feline immunodeficiency virus/human immunodeficiency virus type 1 reverse transcriptase chimeras to non-nucleoside RT inhibitorsJoeri Auwerx
Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
Mol Pharmacol 65:244-51. 2004....
Looking back in 2009 at the dawning of antiviral therapy now 50 years ago an historical perspectiveErik De Clercq
Rega Institute for Medical Research, Department of Microbiology and Immunology, K U Leuven, Leuven, Belgium
Adv Virus Res 73:1-53. 2009....
Ribavirin and mycophenolic acid markedly potentiate the anti-hepatitis B virus activity of entecavirChunxiao Ying
Rega Institute for Medical Research, Faculty of Medicine, Katholieke Universiteit Leuven, Minderbroedersstraat 10, B 3000 Leuven, Belgium
Antiviral Res 73:192-6. 2007....
New approaches toward anti-HIV chemotherapyErik De Clercq
Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium
J Med Chem 48:1297-313. 2005
HIV-chemotherapy and -prophylaxis: new drugs, leads and approachesErik De Clercq
Rega Institute for Medical Research, K U Leuven, Minderbroedersstraat 10, B 3000 Leuven, Belgium
Int J Biochem Cell Biol 36:1800-22. 2004..Taken together, it is obvious that the approaches for the treatment of HIV infections in recent years have become both more diverse and more efficient...
Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infectionsErik De Clercq
Rega Institute for Medical Research, Katholieke Universiteit Leuven, B 3000 Leuven, Belgium
Clin Microbiol Rev 16:569-96. 2003....
Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360Valery Fikkert
Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
AIDS 18:2019-28. 2004..Integrase-chimeric virus technology confirmed that the integrase mutations are indeed fully responsible for the resistance phenotype of IIIB/S-1360...
The imidazopyrrolopyridine analogue AG110 is a novel, highly selective inhibitor of pestiviruses that targets the viral RNA-dependent RNA polymerase at a hot spot for inhibition of viral replicationJan Paeshuyse
Rega Institute for Medical Research, Minderbroedersstraat 10, B 3000 Leuven, Belgium
J Virol 81:11046-53. 2007..It is concluded that a single drug-binding pocket exists within the finger domain region of the BVDV RdRp that consists of two separate but potentially overlapping binding sites rather than two distinct drug-binding pockets...
The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitroJan Paeshuyse
Rega Institute for Medical Research, Leuven, Belgium
Hepatology 43:761-70. 2006....
New class of HIV integrase inhibitors that block viral replication in cell cultureChristophe Pannecouque
Rega Institute for Medical Research, KULeuven, Minderbroedersstraat 10, Belgium
Curr Biol 12:1169-77. 2002..CONCLUSIONS: Based on their mode of action, which is different from that of clinically approved anti-HIV drugs, PDPs are good candidates for further development into new drugs and to be included in future combination regimens...
Acyclic nucleoside phosphonates: a key class of antiviral drugsErik De Clercq
Rega Institute for Medical Research, Katholieke Universiteit Leuven, B 3000 Leuven, Belgium
Nat Rev Drug Discov 4:928-40. 2005....
Drug targets in cytomegalovirus infectionGraciella Andrei
Laboratory of Virology and Chemotherapy, Department of Microbiology and Immunology, Rega Institute for Medical Research, K U Leuven, Belgium
Infect Disord Drug Targets 9:201-22. 2009..This review will focus on new compounds that inhibit a specific viral process (viral targets) and on cell-based approaches (cellular targets) that result in selective inhibition of virus replication...
The design of drugs for HIV and HCVErik De Clercq
Rega Institute for Medical Research, K U Leuven, B 3000 Leuven, Belgium
Nat Rev Drug Discov 6:1001-18. 2007....
Antiviral treatment of chronic hepatitis B virus infections: the past, the present and the futureGeoffrey Férir
Rega Institute for Medical Research, KULeuven, Leuven, Belgium
Rev Med Virol 18:19-34. 2008..Foremost among these newer compounds are adefovir dipivoxil, entecavir and telbivudine...
Synthesis and antiviral activity of some 5'-N-phthaloyl-3'-azido-2',3'-dideoxythymidine analoguesJan Balzarini
Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
Antivir Chem Chemother 14:139-44. 2003..They did not inhibit recombinant HIV-1 reverse transcriptase. All compounds were inactive against HIV in thymidine kinase-deficient cells, pointing to the compounds' requirement to release free AZT to afford antiviral efficacy...
Potent, selective and cell-mediated inhibition of human herpesvirus 6 at an early stage of viral replication by the non-nucleoside compound CMV423Leen De Bolle
Rega Institute for Medical Research, Katholieke Universiteit Leuven, 3000, Leuven, Belgium
Biochem Pharmacol 67:325-36. 2004..We, therefore, conclude that CMV423 exerts its activity against HHV-6 through inhibition of a cellular process that is critical at early stages of viral replication and that may affect protein tyrosine kinase activity...
CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitroKurt Vermeire
Rega Institute for Medical Research, Katholieke Universiteit Leuven, B 3000 Leuven, Belgium
AIDS 18:2115-25. 2004..To evaluate the anti-HIV-1 activity of the cyclotriazadisulfonamide CADA against primary isolates in vitro and the combination of CADA with approved anti-HIV drugs for potential synergy...
Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutationsValery Fikkert
Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium
J Virol 77:11459-70. 2003..As to the replication kinetics of the selected strains, the replication fitness for all strains was lower than that of the wild-type HIV-1 strain...
Pyridine N-oxide derivatives are inhibitory to the human SARS and feline infectious peritonitis coronavirus in cell cultureJan Balzarini
Rega Institute for Medical Research, K U Leuven, Leuven, Belgium
J Antimicrob Chemother 57:472-81. 2006..Evaluation of a wide variety of pyridine N-oxide derivatives on their inhibitory activity against feline coronavirus (FIPV strain) and human SARS-CoV (Frankfurt strain-1) in cell culture...
Inhibition of human immunodeficiency virus by a new class of pyridine oxide derivativesMiguel Stevens
Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium
Antimicrob Agents Chemother 47:2951-7. 2003....
Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonistKatrien Princen
Rega Institute for Medical Research, Minderbroedersstraat 10, B-3000 Leuven, Belgium
J Virol 78:12996-3006. 2004..AMD3451 is the first low-molecular-weight anti-HIV agent with selective HIV coreceptor, CCR5 and CXCR4, interaction...
In search of authentic inhibitors of HIV-1 integrationZeger Debyser
Rega Institute for Medical Research, KU Leuven, Flanders, Belgium
Antivir Chem Chemother 13:1-15. 2002..We point to potential pitfalls in defining an inhibitor as an authentic integrase inhibitor, and propose new strategies and technologies for the discovery of authentic HIV integration inhibitors...
Establishment of a novel CCR5 and CXCR4 expressing CD4+ cell line which is highly sensitive to HIV and suitable for high-throughput evaluation of CCR5 and CXCR4 antagonistsKatrien Princen
Rega Institute for Medical Research, Katholieke Universiteit Leuven, B 3000 Leuven, Belgium
Retrovirology 1:2. 2004..Here, we describe the establishment of a novel CD4+ cell line, U87.CD4.CCR5.CXCR4, stably expressing both CCR5 and CXCR4 at the cell surface...
Ribavirin antagonizes the in vitro anti-hepatitis C virus activity of 2'-C-methylcytidine, the active component of valopicitabineLotte Coelmont
Rega Institute for Medical Research, KULeuven, Leuven, Belgium
Antimicrob Agents Chemother 50:3444-6. 2006..These findings may have implications when planning clinical studies with valopicitabine...
Deoxythreosyl phosphonate nucleosides as selective anti-HIV agentsTongfei Wu
Laboratories of Medicinal Chemistry and Virology, Rega Institute for Medical Research, Minderbroedersstraat 10, Leuven, Belgium
J Am Chem Soc 127:5056-65. 2005..The incorporated PMDTA fits very well in the active site pocket of HIV-1 reverse transcriptase...
Design, synthesis, anti-HIV activities, and metabolic stabilities of alkenyldiarylmethane (ADAM) non-nucleoside reverse transcriptase inhibitorsMaximilian A Silvestri
Department of Medicinal Chemistry and Molecular Pharmacology, School of Pharmacy and Pharmacal Sciences, Purdue University, West Lafayette, IN 47907, USA
J Med Chem 47:3149-62. 2004..8 microM level. At the same time, the bis(thioester) modification was less cytotoxic to uninfected MT-4 cells, with a CC(50) of >224 microM versus 160 microM for the parent compound...
Sugar-modified conjugated diene analogues of adenosine and uridine: synthesis, interaction with S-adenosyl-L-homocysteine hydrolase, and antiviral and cytostatic effectsStanislaw F Wnuk
Department of Chemistry, Florida International University, Miami, FL 33199, USA
J Med Chem 45:2651-8. 2002..7 microM and cytostatic at > or =11 microM, while dienoic esters 16a,b showed activity against both varicella-zoster virus (at 10 microM, 16a) and cytomegalovirus (at 10 microM, 16a; 18 microM, 16b)...
Synthesis of new 2,3-diaryl-1,3-thiazolidin-4-ones as anti-HIV agentsAngela Rao
Dipartimento Farmaco-Chimico, , Viale Annunziata, 98168, Messina, Italy
Farmaco 59:33-9. 2004....
Hybrids of [TSAO-T]-[foscarnet]: The first conjugate of foscarnet with a non-nucleoside reverse transcriptase inhibitor through a labile covalent ester bondSonsoles Velazquez
Instituto de Química Médica C S I C, Juan de la Cierva 3, E 28006 Madrid, Spain
J Med Chem 47:3418-26. 2004..Moreover, stability studies of the [TSAO-T]-[PFA] conjugates demonstrated that the compounds were stable in PBS whereas some of the conjugates regenerated the parent inhibitors in extracts from CEM cells...
Synthesis and anti-HIV-1 and anti-HCMV activity of 1-substituted 3-(3,5-dimethylbenzyl)uracil derivativesTokumi Maruyama
Faculty of Pharmaceutical Sciences at Kagawa Campus, Tokushima Bunri University, Shido, Samuki, Japan
Chem Pharm Bull (Tokyo) 54:325-33. 2006..These results were confirmed by Docking Studies using the program, Glide ligand docking jobs, which suggests hydrogen bonding between amide N-H of Lys 101 and nitrogen of the cyanomethyl and picolyl group...
Synthesis and antiviral activity of 1,3-disubstituted uracils against HIV-1 and HCMVTokumi Maruyama
Faculty of Pharmaceutical Sciences, Tokushima Bunri University, Tokushima, Japan
Antivir Chem Chemother 14:271-9. 2003..We found that 1-benzyl-3-(3,5-dimethylbenzyl)uracil and 1-cyanomethyl-3-(3,5-dimethylbenzyl)-4-thiouracil showed powerful inhibition against HCMV and HIV-1, respectively...
5-Substituted-2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidines-acyclic nucleoside phosphonate analogues with antiviral activityDana Hocková
Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Flemingovo nam 2, CZ 166 10, Prague 6, Czech Republic
J Med Chem 46:5064-73. 2003..0023-0.0110 mumol/mL), comparable to that of the reference drugs adefovir and tenofovir, but were devoid of measurable toxicity at 0.3 mumol/mL...
Design and synthesis of phosphonoacetic acid (PPA) ester and amide bioisosters of ribofuranosylnucleoside diphosphates as potential ribonucleotide reductase inhibitors and evaluation of their enzyme inhibitory, cytostatic and antiviral activityStefano Manfredini
Department of Pharmaceutical Sciences, University of Ferrara, Ferrara, Italy
Antivir Chem Chemother 14:183-94. 2003....
Synthesis and antiviral activities of 3-aralkylthiomethylimidazo[1,2-b]pyridazine derivativesChristophe Galtier
, , Tours, France
Antivir Chem Chemother 14:177-82. 2003..The results presented here suggest that compound 10 should be considered as a new lead in the development of antiviral agents...
Database searching for thymidine and thymidylate kinase inhibitors using three-dimensional structure-based methodsDavid T Manallack
Celltech R and D Ltd, Great Abington, Cambridge, UK
J Enzyme Inhib Med Chem 17:167-74. 2002..The best of these compounds was only 4.6-fold less potent than 3'-azido-3'-deoxythymidine-5'-monophosphate (AZTMP). This study demonstrates the utility of structure-based drug design methods in the search for novel enzyme inhibitors...
Design, synthesis, structure-activity relationships, and molecular modeling studies of 2,3-diaryl-1,3-thiazolidin-4-ones as potent anti-HIV agentsMaria L Barreca
Dipartimento Farmaco-Chimico, , Viale Annunziata, 98168 Messina, Italy
J Med Chem 45:5410-3. 2002..Computational studies were used to delineate the ligand-RT interactions and to probe the binding of the ligands to HIV-1 RT...
Bone marrow transplantation in a child with Wiskott-Aldrich syndrome latently infected with acyclovir-resistant (ACV(r)) herpes simplex virus type 1: emergence of foscarnet-resistant virus originating from the ACV(r) virusMasayuki Saijo
Special Pathogens Laboratory, Department of Virology 1, National Institute of Infectious Diseases, Tokyo, Japan
J Med Virol 68:99-104. 2002..This is the first report on the clinical course of a BMT-associated ACV(r) HSV-1 infection that subsequently developed resistance to foscarnet as well...
Nitroimidazoles. V. Synthesis and anti-HIV evaluation of new 5-substituted piperazinyl-4-nitroimidazole derivativesYaseen A Al Soud
Department of Chemistry, College of Science, University of Al al Bayt Al Mafraq, Jordan
Acta Pharm 57:379-93. 2007..Compound 4 showed inhibition of HIV-1 (EC50 0.45 microg mL-1) and HIV-2 (0.50 microg mL-1), while 11 showed inhibition of HIV-1 (EC50 2.48 microg mL-1, SI = 4)...
Efficient 3D database screening for novel HIV-1 IN inhibitorsMaria Letizia Barreca
Dipartimento Farmaco Chimico, Universita di Messina, Viale Annunziata, 98168 Messina, Italy
J Chem Inf Comput Sci 44:1450-5. 2004..Biological testing shows that our strategy was successful in searching for new structural leads as HIV-1 IN inhibitors...
Nonnucleoside HIV-1 reverse transcriptase inhibitors; part 3. Synthesis and antiviral activity of 5-alkyl-2-[(aryl and alkyloxyl-carbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-onesYanping He
Department of Chemistry, Fudan University, Shanghai 200433, People's Republic of China
Bioorg Chem 32:536-48. 2004....
Synthesis and anti-HIV activity of new alkenyldiarylmethane (ADAM) non-nucleoside reverse transcriptase inhibitors (NNRTIs) incorporating benzoxazolone and benzisoxazole ringsBo-Liang Deng
Department of Medicinal Chemistry and Molecular Pharmacology and Purdue Cancer Center, School of Pharmacy and Pharmaceutical Sciences, Purdue University, West Lafayette, IN 47907, USA
Bioorg Med Chem 14:2366-74. 2006....
Selective inhibition of porcine endogenous retrovirus replication in human cells by acyclic nucleoside phosphonatesMinyi Shi
Frontier Science Research Center, Kagoshima University, Kagoshima 890 8544, Japan
Antimicrob Agents Chemother 51:2600-4. 2007..Among the test compounds, zidovudine was found to be the most active. The order of potency was zidovudine > phosphonylmethoxyethoxydiaminopyrimidine = phosphonylmethoxypropyldiaminopurine > tenofovir > or = adefovir > stavudine...
Synthesis and evaluation of 2-(2,6-dihalophenyl)-3-pyrimidinyl-1,3-thiazolidin-4-one analogues as anti-HIV-1 agentsRavindra K Rawal
Medicinal and Process Chemistry Division, Central Drug Research Institute, Lucknow 226 001, India
Bioorg Med Chem 15:3134-42. 2007..These models also indicate a preference for hydrophobic compounds to obtain good HIV-1 RT inhibitory activity...
Synthesis and antiviral evaluation of cyclic and acyclic 2-methyl-3-hydroxy-4-pyridinone nucleoside derivativesKarine Barral
, GCOM2, UMR CNRS 6114, , Case 901, 163 av. de Luminy, 13288 Marseille Cedex 9, France
J Med Chem 49:43-50. 2006..Some compounds showed moderate activity against both wild-type HSV-1 and HSV-2, as well as against a thymidine kinase deficient strain of HSV-1. These results suggest a novel mode of action for this group of nucleoside analogues...
Nitroimidazoles, part 2: Synthesis, antiviral and antitumor activity of new 4-nitroimidazolesNajim A Al-Masoudi
Fachbereich Chemie, Universitat Konstanz, Postfach 5560, D 78457 Konstanz
Chem Biodivers 3:515-26. 2006..Yet, the therapeutic index of compounds 17 and 21 for CMV and VZV approached the tenfold cut-off point. Compounds 8 and 21 exhibited some cytostatic activity against leukemia and melanoma cell lines...
Synthesis and anti-HIV activity of novel cyclopentenyl nucleoside analogues of 8-azapurinePilar Canoa
, , Universidad de Vigo, Vigo, Spain
Chem Pharm Bull (Tokyo) 54:1418-20. 2006..The chlorine derivative 3 inhibited both HIV-1 and HIV-2 replication in MT-4 cells with IC(50) values of 10.67 microM and of 13.79 microM, respectively...
Synthesis and anti-BVDV activity of acridones as new potential antiviral agentsOriana Tabarrini
Dipartimento di Chimica e Tecnologia del Farmaco, Universita degli Studi di Perugia, Via del Liceo 1, 06123 Perugia, Italy
J Med Chem 49:2621-7. 2006..Thus, the acridone scaffold, when appropriately functionalized, can yield compounds with selective activity against pestiviruses and related viruses such as the HCV...
Replacement of the metabolically labile methyl esters in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors with isoxazolone, isoxazole, oxazolone, or cyano substituentsBo-Liang Deng
Department of Medicinal Chemistry and Molecular Pharmacology and the Purdue Cancer Center, School of Pharmacy and Pharmaceutical Sciences, Purdue University, West Lafayette, Indiana 47907, USA
J Med Chem 49:5316-23. 2006..The methyl ester and methoxy substituents on both of the aromatic rings in the parent compound 1 were successfully replaced with metabolically stable moieties with retention of anti-HIV activity and a general decrease in cytotoxicity...
Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infectionsGeorge R Painter
Chimerix Incorporated, Durham, NC 27713, USA
Antimicrob Agents Chemother 51:3505-9. 2007..Consequently, CMX157 represents a second-generation tenofovir analog which may have an improved clinical profile...
Non-nucleoside HIV reverse transcriptase inhibitors, Part 6[1]: synthesis and anti-HIV activity of novel 2-[(arylcarbonylmethyl)thio]-6-arylthio DABO analoguesGuang-Fu Sun
Department of Chemistry, Fudan University, Shanghai, People's Republic of China
Arch Pharm (Weinheim) 338:457-61. 2005..37-29.50 microM, and the IC(50) values for anti-HIV-2 activity fall into the range 23.11-181.07 microM. The results indicated that these compounds are moderately active against HIV-1 and HIV-2...
Dipeptide derivatives of AZT: synthesis, chemical stability, activation in human plasma, hPEPT1 affinity, and antiviral activityCledir Santos
CIQUP, Departamento de Quimica, Faculdade de Ciencias, Universidade do Porto, R Campo Alegre 687, 4169 007 Porto, Portugal
ChemMedChem 3:970-8. 2008..Val-Ala-AZT appears to combine chemical stability with good affinity for the hPEPT1 transporter and an improved cytotoxicity/antiretroviral index relative to AZT...
Synthesis, anti-HIV-1 activity, and modeling studies of N-3 Boc TSAO compoundCyrille Tomassi
Laboratoire des Glucides UMR6219, Universite de Picardie Jules Verne, 33 rue Saint Leu, 80039 Amiens, France
Bioorg Med Chem Lett 18:2277-81. 2008..The computational analysis showed that the N-3 Boc group promotes new interactions in the binding site of the enzyme leading to a good inhibitory activity...
Synthesis and anti-HIV activity evaluation of novel 2,4-disubstituted 7-methyl-1,1,3-trioxo-2,4-dihydro-pyrazolo-[4,5-e][1,2]thiadiazinesXin Yong Liu
Institute of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University, Jinan, PR China
Arch Pharm (Weinheim) 341:216-22. 2008..The most active HIV-2 inhibitor was compound 7i (R1 = benzyl, R2 = 4-t-butyl-benzyl) with an EC50 value of 18.7 microM and SI=15, which may provide a useful lead for further molecular optimization...
Non-nucleoside HIV-1 reverse-transcriptase inhibitors. Part 10. Synthesis and anti-HIV activity of 5-alkyl-6-(1-naphthylmethyl)pyrimidin-4(3H)-ones with a mono- or disubstituted 2-amino function as novel 'dihydro-alkoxy-benzyl-oxopyrimidine' (DABO) analogYueping Wang
Department of Chemistry, Fudan University, Shanghai 200433, PR China
Chem Biodivers 5:168-76. 2008..Preliminary structure-activity relationship (SAR) studies revealed that both modulation of the amino function at C(2) and of the alkyl group at C(5) of the pyrimidine ring are crucial for high anti-HIV-1 activity...
